MedPage Today on MSN21h
NMO Drug Looks Good for IgG4-Related Disease
WASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for ...
Science Daily19h
Clinical trial shows positive results for potential treatment to combat a challenging rare disease
Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).